Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheuminations: Rheumatologists Seek Better Understanding of Fibrosing Disorders

Simon M. Helfgott, MD  |  Issue: December 2013  |  December 1, 2013

My single encounter with EMS occurred one month after the Morbidity and Mortality Weekly Report had reported these first cases. Margaret was a 50-year-old woman who, on the advice of her psychiatrist, had started using L-tryptophan as a sleep supplement. He believed that this was a safer therapeutic alternative than having her continue taking diazepam to help her sleep. Sadly, her demise is best depicted by Dr. Osler’s quotation about scleroderma and mummies. The fatal blow came when Margaret developed a marked axonal neuropathy, resulting in a rapidly ascending polyneuropathy with the development of a near-total quadriplegia. Her tragic battle with EMS finally came to an end.

Recently, with the advent of new imaging techniques, we began witnessing a new disorder, nephrogenic systemic fibrosis (NSF). This generalized fibrotic disease developed in some patients with renal insufficiency following exposure to gadolinium-based contrast agents that were used to enhance magnetic resonance imaging. Clinically, NSF shares many common features with SSc, including severe and usually progressive skin induration, incapacitating joint flexion contractures, and fibrotic involvement of the lungs, heart, and other organs. Recent evidence suggests that exposure to gadolinium-based contrast agents results in the increased production and expression of numerous proinflammatory and profibrotic cytokines, chemokines, and growth factors.8

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

(For additional information, please refer to “Gadolinium Compounds Provide Insights into Pathogenesis of Fibrosing Diseases” at www.The-Rheumatologist.org.)

EMS, toxic oil syndrome, NFD, and other conditions including eosinophilic fasciitis and graft-versus-host disease can all mimic SSc. Unfortunately, our current understanding of the pathogenesis of these disorders has not led to a deeper understanding of SSc. The mystery remains unsolved.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A Painter’s Legacy

How did Paul Klee’s illness influence his art? In the year that he was diagnosed with SSc, he produced just 25 works, but three years later this number mushroomed to more than 1,200 pieces. What about the nature of his final years? According to Varga, Klee’s creative genius was fundamentally shaped by his illness.2 The lightheartedness and wit of his early works gave way to introspection and despair. Abstract figures were painted with simple, heavy black lines. Some even seemed to be childish or primitive. He abandoned painting intricate, small-scale compositions for much larger pieces. In some of his later art (“The Mask,” 1940, and “Captive,” 1940), the viewer can witness some of the profound changes in Klee’s personal appearance and his sense of being trapped inside a prison. Though Klee was dying and the world around him was collapsing amid the chaos of the Second World War, he found a way to persevere. Like Tithonus, “he withered slowly,” but unlike him, he refused “to be beaten down and marred and wasted.”

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:fibrosisPathogenesisRaynaud’s phenomenonSclerodermaSystemic sclerosis

Related Articles

    Capillaroscopy a Safe and Direct Method for SSc Diagnosis

    June 13, 2011

    Seeing vessels clearly can help with discovery and timely treatment

    Targeted Therapy for Scleroderma Fibrosis

    October 11, 2016

    Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a prevalence in North America of approximately 300 per 1 million people, SSc is associated with significant morbidity and high rates of mortality.1 Patients with scleroderma have four times greater mortality than age- and sex-matched controls, with…

    More Effective Antifibrotic Therapies for Systemic Sclerosis in Development; Adverse Events A Concern

    June 14, 2017

    Systemic sclerosis (SSc) is a rare disease affecting about 49,000 U.S. adults, and it is strongly associated with high levels of morbidity and mortality.1 Of the few available antifibrotic therapies, none is targeted for SSc. However, reason for optimism exists for antifibrotic treatments in early development and clinical trials, says Jörg H.W. Distler, MD, Heisenberg Professor…

    Labored Breathing

    January 1, 2007

    Strategies to diagnose and manage dyspnea in the scleroderma patient

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences